English
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)
cyclooxygenase/neoplasms
The link is saved to the clipboard
Page 1 from 46 results
Method for inhibiting cyclooxygenase-2 and tumor necrosis factor alpha
Only registered users can translate articles
Log In/Sign up
BACKGROUND OF THE INVENTION
1. Field of the Invention
The present invention relates to methods for inhibiting cyclooxygenase-2 (COX-2) and tumor necrosis factor alpha (TNF.alpha.) activities and treating disorders and diseases associated with elevated COX-2 and TNF.alpha. activities.
2. Description
Indolinone protein kinase inhibitors and cyclooxygenase inhibitors for use in combination therapy for the treatment of cancer
Only registered users can translate articles
Log In/Sign up
BACKGROUND OF THE INVENTION
1. Field of the Invention
The present invention relates to methods for treatment or prevention of neoplasia disorders using protein tyrosine kinase inhibitors in combination with cyclooxygenase inhibitors, in particular cyclooxygenase-2 selective inhibitors.
2. State of
Method of using cyclooxygenase-2 inhibitors in the treatment and prevention of neoplasia
Only registered users can translate articles
Log In/Sign up
FIELD OF THE INVENTION
This invention is in the field of the prevention and treatment of neoplasia. More specifically, this invention relates to the use of cyclooxygenase-2 inhibitors or derivatives thereof in preventing and treating neoplasia.
BACKGROUND OF THE INVENTION
Prostaglandins play a major
Method of using cyclooxygenase-2 inhibitors in the treatment and prevention of neoplasia
Only registered users can translate articles
Log In/Sign up
FIELD OF THE INVENTION
This invention is in the field of the prevention and treatment of neoplasia. More specifically, this invention relates to the use of cyclooxygenase-2 inhibitors or derivatives thereof in preventing and treating neoplasia.
BACKGROUND OF THE INVENTION
Prostaglandins play a major
Combination dosage of a cyclooxygenase (COX) inhibitor, a vitamin D.sub.3 including analogues and metabolites thereof and/or calcium for prevention of epithelial cancer
Only registered users can translate articles
Log In/Sign up
In recent years, focus is very much on cancer prevention, in acknowledgement of the fact that surgery mostly does not suffice as the only modality and that most cytotoxic regimens are ineffective against solid tumours. With the choices and results of treatment known today, only effective prevention
Epigenetic silencing of cyclooxygenase-2 affects clinical outcome in gastric cancer
Only registered users can translate articles
Log In/Sign up
FIELD OF THE INVENTION
The present invention relates in general to cancer. More specifically, the invention provides methods of predicting disease outcome in gastric cancer patients based on the methylation status of the Cox-2 gene promoter region.
SEQUENCE LISTING
The present invention contains
Epigenetic silencing of cyclooxygenase-2 affects clinical outcome in gastric cancer
Only registered users can translate articles
Log In/Sign up
FIELD OF THE INVENTION
The present invention relates in general to cancer. More specifically, the invention provides methods of predicting disease outcome in gastric cancer patients based on the methylation status of the Cox-2 gene promoter region.
SEQUENCE LISTING
The present invention contains
Screening assays for cancer chemopreventative agents
Only registered users can translate articles
Log In/Sign up
TECHNICAL AREA OF THE INVENTION
The invention relates to the area of cancer chemopreventative agents. More particularly, the invention relates to the area of screening assays for cancer chemopreventative agents.
BACKGROUND OF THE INVENTION
Because common epithelial cancers have resisted most
Treating cancers associated with overexpression of HER-2/neu
Only registered users can translate articles
Log In/Sign up
TECHNICAL FIELD
This invention is directed to treatment of HER-2/neu overexpressing cancers.
BACKGROUND OF THE INVENTION
The HER-2/neu (erbB-2) gene product is a 185-kDA transmembrane receptor tyrosine kinase that belongs to the family of receptors for epidermal growth factor. It is described in
Cyclooxygenase-2 inhibitor/histone deacetylase inhibitor combination
Only registered users can translate articles
Log In/Sign up
The invention relates to a combination which comprises (a) a cyclooxygenase-2 inhibitor ("COX-2 inhibitor") and (b) a histone deacetylase Inhibitor ("HDAI") for simultaneous, concurrent, separate or sequential use, especially for use in the treatment of pre-malignant colon lesions or a colon cancer
Medicinal compositions for treating colorectal cancer
Only registered users can translate articles
Log In/Sign up
TECHNICAL FIELD
The invention relates to a pharmaceutical composition to be administered to the large intestine for treating a colorectal cancer.
BACKGROUND ART
In cancer therapy the surgical treatment is the mainstream at present. However, in order to improve the performance of the surgical
Indomethacin analogs for the treatment of castrate-resistant prostate cancer
Only registered users can translate articles
Log In/Sign up
TECHNICAL FIELD
The presently disclosed subject matter relates to methods and compositions for inhibiting a biological activity of a human aldo-keto reductase family 1, member C3 (AKR1C3; also known as type 5 17.beta.-hydroxysteroid dehydrogenase) polypeptide. In some embodiments, the compositions
Indomethacin analogs for the treatment of castrate-resistant prostate cancer
Only registered users can translate articles
Log In/Sign up
TECHNICAL FIELD
The presently disclosed subject matter relates to methods and compositions for inhibiting a biological activity of a human aldo-keto reductase family 1, member C3 (AKR1C3; also known as type 5 17.beta.-hydroxysteroid dehydrogenase) polypeptide. In some embodiments, the compositions
Indomethacin analogs for the treatment of castrate-resistant prostate cancer
Only registered users can translate articles
Log In/Sign up
TECHNICAL FIELD
The presently disclosed subject matter relates to methods and compositions for inhibiting a biological activity of a human aldo-keto reductase family 1, member C3 (AKR1C3; also known as type 5 17.beta.-hydroxysteroid dehydrogenase) polypeptide. In some embodiments, the compositions
1-(4-sulfamylaryl)-3-substituted-5-aryl-2-pyrazolines and inhibitors of cyclooxygenase-2
Only registered users can translate articles
Log In/Sign up
FIELD OF THE INVENTION
The invention relates generally to anti-inflammatory drugs, and more particularly to novel compounds which inhibit the activity of cyclooxygenase-2.
BACKGROUND OF THE INVENTION
The metabolites of arachidonic acid, such as prostaglandins, lipoxygenases and thromboxane products
The most complete medicinal herbs database backed by science
- Works in 55 languages
- Herbal cures backed by science
- Herbs recognition by image
- Interactive GPS map - tag herbs on location (coming soon)
- Read scientific publications related to your search
- Search medicinal herbs by their effects
- Organize your interests and stay up do date with the news research, clinical trials and patents
Type a symptom or a disease and read about herbs that might help, type a herb and see diseases and symptoms it is used against.
*All information is based on published scientific research
